Background: It is clinically important to estimate the degree of endothelial dysfunction. Several methods have been used to assess endothelial function in humans. Recently, we developed a new noninvasive method for measurement of vascular response to reactive hyperemia in the brachial artery, named enclosed zone flow-mediated vasodilation (ezFMD). The purpose of this study was to determine the validity of ezFMD for assessment of endothelial function.
Introduction
Endothelial dysfunction is an early feature of atherosclerosis and vascular diseases in humans [1] . It is clinically important to estimate the degree of endothelial dysfunction. Several methods have been used to assess endothelial function in humans [2e19] . Recently, several investigators, including us, have evaluated the effects of intra-arterial infusion of nitric oxide (NO) agonists, such as acetylcholine, methacholine, and bradykinin, and the effects of intra-arterial infusion of NO antagonists on forearm blood flow using a mercury-filled silastic strain-gauge plethysmography and the effects on coronary blood flow using a Doppler flow guide wire [2e14] . Responses to intra-arterial infusion of vasoactive agents should be considered as the gold standard for assessing endothelial function, because the use of agonists to stimulate NO release and the use of antagonists of NO allow us to draw more specific conclusions concerning the role of basal and stimulated NO release. However, the invasive methods are time-consuming and are a burden for patients. Measurement of flow-mediated vasodilation (FMD) in the brachial artery using ultrasound is noninvasive and is an accurate indicator of NO production [15e19]. However, evaluation by FMD measurement requires skill in measurement of the vessel diameter by an ultrasound system, and the FMD measurement system is difficult to handle. Moreover, the technique requires a large-scale apparatus.
Blood pressure can be easily and noninvasively measured by an automatic device using an oscillometric method. When measuring blood pressure by an automatic device, oscillation amplitude can be measured at the same time. We hypothesized that change in oscillation amplitude caused by ischemia could reflect FMD, since change in oscillation amplitude caused by ischemia is proportional to vessel volumetric change. In other words, conventional FMD is measured by change in vascular diameter, whereas ezFMD is measured by change in vascular volume. In accordance with this theory, we recently developed a new noninvasive and simple method for measurement of vascular response to reactive hyperemia in the brachial artery, named enclosed zone FMD (ezFMD).
In this study, we evaluated the usefulness of ezFMD for assessment of endothelial function and compared the results obtained by ezFMD and conventional FMD.
Methods

Subjects
We studied 306 subjects, including hypertension, dyslipidemia, and diabetes mellitus (218 men and 88 women, 30 AE 16 yr). Hypertension was defined as systolic blood pressure of more than 140 mm Hg and/or diastolic blood pressure of more than 90 mm Hg, in a sitting position, on at least three different occasions. Patients with secondary forms of hypertension were excluded on the basis of complete history, physical examination, radiological and ultrasound examinations, urinalysis, plasma renin activity, plasma aldosterone and norepinephrine concentrations, serum creatinine, potassium, calcium, and free thyroxine concentrations, and 24-h urinary excretion of 17-hydroxycorticosteroids, 17-ketogenic steroids, and vanillymandelic acid. Normotension was defined as systolic blood pressure of less than 140 mm Hg and diastolic blood pressure of less than 90 mm Hg. Diabetes was defined according to the American Diabetes Association [20] and/or a previous diagnosis of diabetes. Dyslipidemia was defined according to the third report of the National Cholesterol Education Program [21] . Current smokers were defined as any who had smoked at least 1 packyear. One pack-year was defined as 20 cigarettes per day for 1 year. All of the smokers (18.5 AE 8.7 pack-years) had a current smoking history of more than 5 years and abstained from smoking for at least 3 h before the measurement of vascular function. We defined nonsmokers as those who had never smoked. The study protocol was approved by the Ethical Committee of Hiroshima University Graduate School of Biomedical Sciences. Informed consent for participation in the study was obtained from all subjects.
Study protocol
All studies were performed in the morning, after overnight fasting, in a quiet, dark, air-conditioned room (constant temperature of 22e25 C). Measurements of ezFMD and FMD were randomly performed on separate day. None of the subjects were taking oral antioxidant vitamins or vasoactive drugs, including antihypertensive agents, antidiabetic agents and statins before the study.
Subjects fasted the previous night for at least 12 h. Thirty minutes after remaining in the supine position, fasting serum concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and glucose were measured.
Measurement of ezFMD
Oscillometric noninvasive blood pressure measurement is widely performed in a clinical setting. The theory is that the arterial wall contains zero stress and the vessel is minimally distended when external or cuff pressure is equal to arterial pressure [22, 23] . Cuff wave pressure is a signal of variation of internal cuff pressure and arises from volumetric change in the cuff, which, in turn, originates from volumetric pulse change in the artery. When arterial vessel volume increases, cuff volume decreases and cuff internal pressure increases. Repetition of changes in arterial vessel volume and cuff volume shows the oscillation signal. The magnitude of oscillation and volumetric change in the artery shows a close proportional relation. Cuff pressure associated with the largest oscillation amplitude can be considered as mean blood pressure. Supplemental Fig. S1A shows the relationship between cuff pressure and oscillation amplitude. A pressure at the largest oscillation during the deflation period as mean blood pressure and determines systolic blood pressure and diastolic blood pressure at 50% of the largest one are obtained (Supplemental Fig. S1B ). The vascular response to reactive hyperemia in the brachial artery was assessed for oscillation amplitude measurement of ezFMD. We assessed pulse wave with an OPV 1500 (Nihon Koden. Co., Tokyo, Japan) (Supplemental Fig. S2 ). Oscillometry is a commonly used noninvasive method for measuring blood pressure with a sphygmomanometer cuff tied around the upper arm. After the cuff is inflated to a level higher than systolic blood pressure, it is deflated slowly, and blood pressure is estimated on the basis of oscillation signals recorded from the internal cuff pressure. At first, we measured blood pressure five times on the proximal forearm in the seated position at rest with this device, and after interrupting blood flow for 5 min with the cuff, we measured blood pressure for 5 min consecutively automatically. We adopted each maximal oscillation. The cuff was inflated up to systolic pressure plus 50 mmHg. For every cuff pressure deflation of 5 mmHg, two oscillation signal pulses were detected. In each step, detection of two oscillation signal pulses and deflation of the cuff were repeated, and cuff pressure was released at the point when diastolic pressure was reached. The average of the oscillation amplitude of two pulses was considered as the typical value of the oscillation amplitude at each cuff pressure step. We used the maximum typical value of one measurement sequence to calculate the compliance change. ezFMD was calculated by the following equation: %ezFMD ¼ [(peak oscillation amplitudeÀbaseline oscillation amplitude)/baseline oscillation amplitude] Â 100 (Fig. 1, A and B ). In the after-occlusion period, the average of the third to fifth of 5 measurements was used for analysis of peak oscillation amplitude. Two observers who were blind to the form of examination performed the measurements. The coefficients of variation of intra-and inter-observer ezFMD measurements were 3.8% and 5.9%, respectively.
Measurement of conventional FMD
FMD was assessed using an ultrasonograph (UNEXEF18G, UNEX Co., Nagoya, Japan) as previously described [24, 25] . Please see the online data supplement for additional details.
Theoretical relationship between ezFMD and FMD
We hypothesized the theoretical correlation between ezFMD and FMD. Please see the online data supplement for additional details.
Statistical analysis
Results are presented as means AE SD. All reported P values were 2-sided, and a P value of <0.05 was considered statistically significant. Unpaired Student's t test was used for comparison of mean values of parametric continuous variables between the two groups. Categorical variables were compared by the chi-square test. Relations between variables were determined by liner regression analysis. Relation between ezFMD and FMD was assessed using Pearson's correlation coefficients analysis. Multivariate regression analyses were performed to identify independent factors associated with ezFMD in risk factors and laboratory data. The receiver operating characteristic (ROC) curve analyses was carried out to assess the sensitivity and specificity of measurements of ezFMD and FMD for diagnosing cardiovascular diseases. The data were processed using the software package Stata version 9 (Stata Co., College Station, Texas, USA).
Results
Clinical characteristics
Baseline clinical characteristics in subjects are summarized in Table 1 . Table 2 shows vascular functions in all subjects. ezFMD was significantly lower in patients with cardiovascular diseases (CVDs) (n ¼ 72, 49 men, 58 AE 12 yr) than in age-and gender-matched healthy subjects (n ¼ 72, 49 men, 57 AE 14 yr) (25.8 AE 18.4% vs. 43.2 AE 18.6%, P < 0.0001) (Fig. 2) . There was no significant difference between baseline oscillation amplitudes in the two groups. Univariate regression analysis revealed that ezFMD significantly correlated with age (r ¼ À0.42, P < 0.0001), body mass index (r ¼ À0.13, P ¼ 0.0281), systolic blood pressure (r ¼ À0.15, P ¼ 0.0099), diastolic blood pressure (r ¼ À0.14, P ¼ 0.0108), fasting glucose level (r ¼ À0.27, P ¼ 0.0056), smoking (r ¼ À0.21, P ¼ 0.0071) and baseline oscillation amplitude (r ¼ À0.51, P < 0.0001) (Tables 3a  and b) . ezFMD significantly correlated with conventional FMD (r ¼ 0.34, P < 0.0001) (Fig. 3) . Multiple regression analysis revealed that age, body mass index, systolic blood pressure, smoking, and baseline oscillation amplitude were independent predictors of ezFMD (Tables 3a and b ).
ezFMD
FMD
FMD was significantly lower in patients with CVD (n ¼ 72, 49 men, 58 AE 12 yr) than in age-and gender-matched healthy subjects (n ¼ 72, 49 men, 57 AE 14 yr) (4.5 AE 2.1% vs. 6.9 AE 2.7%, P ¼ 0.0012). There was no significant difference between the two groups baseline brachial artery diameter and reactive hyperemic flow.
Univariate regression analysis revealed that FMD significantly correlated with age (r ¼ À0.28, P ¼ 0.0005), body mass index (r ¼ À0.17, P ¼ 0.0090), systolic blood pressure (r ¼ À0.13, P ¼ 0.0398), fasting glucose level (r ¼ À0.37, P ¼ 0.0002), smoking (r ¼ À0.17, P ¼ 0.0077) and baseline brachial artery diameter (r ¼ À0.42, P < 0.0001) (Tables 4a and b) . Multiple regression analysis revealed that age, systolic blood pressure, and baseline brachial artery diameter were independent predictors of FMD (Tables 4a and b) .
Diagnostic accuracy of ezFMD and FMD
The ROC curves of ezFMD and FMD for diagnosing CVD history are shown in Fig. 4 . The area under the curve values of ROC curves for ezFMD and FMD to diagnose CVD were 0.705 and 0.673 (P < 0.0001), respectively.
Discussion
We developed a new device for fully automatic measurement of endothelial function using an oscillometric method, named ezFMD. Conventional measurement of FMD using ultrasonography is measured by change in vascular diameter, whereas ezFMD is measured by change in vascular volume. Although both ezFMD and FMD are equally useful for assessing endothelial function, measurement of ezFMD is easier and less biased than measurement of FMD.
It is accepted that measurement of forearm blood flow responses to vasoactive agents by plethysmography is an index of resistance artery endothelial function and that measurement of FMD is an index of conduit artery endothelial function, suggesting that plethysmography and FMD measurement do not assess similar endothelial function. The measurement principle of ezFMD is similar to that of FMD. Thus, we compared measurements of ezFMD and FMD. 53 (17) All results are presented as mean AE SD.
In the present study, we confirmed that ezFMD correlated with conventional cardiovascular risk factors, including age, body mass index, blood pressures, glucose, and smoking. Age, systolic blood pressure, smoking, and baseline oscillation amplitude were independent predictors of ezFMD. ezFMD was significantly lower in patients with CVDs than in healthy subjects. Although there was no significant difference in the ROC curves for diagnosing CVD history between ezFMD and FMD, the value of ezFMD tended to be high compared with that of FMD. These findings suggest that measurements of ezFMD as well as FMD are useful for assessing endothelial function. Several lines of evidence have shown that assessment of endothelial function, including vascular responses to vasoactive agents and FMD, can serve as an independent predictor of cardiovascular events. It is expected that ezFMD will also become a surrogate marker for the grade of atherosclerosis and cardiovascular outcomes.
Measurement of ezFMD has a number of advantages as follows. Since only measurement of the amplitude of oscillation is required, the analyzing unit does not need to have a high processing capacity. When measuring conventional FMD by an ultrasound system, the observer has to set a transducer to image the brachial artery and has to measure the changes in brachial artery diameter manually or using tracking software. A high level of technical skills is required to use an ultrasound system, especially when using a transducer, as described in the guidelines for FMD measurement [26e28]. In addition, an ultrasound system is very expensive. When measuring ezFMD, all that is required is to place a cuff on the arm as for measurement of blood pressure. Therefore, artificial bias, including manipulation of the transducer and operation of the ultrasound system, can be avoided by measurement of ezFMD. Consequently, the present invention is advantageous in operation.
Change in vascular volume after pressure stimulation is measured, and information equivalent to that obtained by the reliable FMD method can thus be easily obtained, and the measurement can be performed by a technique and configuration that are similar to those for blood pressure measurement. Therefore, technical skills for measurement are not required. The vessel volumetric change obtained in the present invention is the change of vascular volume in the area where the cuff is attached. The cuffattached area is constant in a series of measurements, and hence the vessel volumetric change can be deemed as a change in vessel sectional area. While change in vessel diameter is obtained by the FMD method, the square of the vessel diameter can be deemed as the sectional area. An idle period when the cuff pressurization is stopped exists between the pressure stimulation and the oscillation amplitude measurement. Therefore, a continuous vessel blocking period is minimized and the burden for the subject is therefore reduced.
In the present study, there was a weak association between ezFMD and FMD and there were relative strong correlations of ezFMD with age, SBP and baseline arterial diameter, suggesting that ezFMD is more strongly related to arterial stiffness and/or blood pressure than to FMD. These findings suggest that ezFMD is more effective than FMD for confirming the atherosclerosis and indicate the possibility that ezFMD is superior to FMD. In other words, ezFMD may be a new marker including both indices of endothelial function and arterial stiffness. Measurements of arterial stiffness parameters would be helpful to confirm the concept that ezFMD includes components of both endothelial function and arterial stiffness.
Study limitations
We hypothesized a theoretical correlation in which the value of ezFMD is approximately two-times higher than that of FMD. However, in the present study, the value of ezFMD was approximately four-times higher than that of FMD. Guidelines for management of FMD recommend the forearm occlusion method [26e 28]. Unfortunately, when the occlusion cuff was placed on the forearm, signals of oscillation after cuff release were not completely obtained. Therefore, we selected the upper arm cuff occlusion method to measure ezFMD. FMD in the brachial artery was measured using a forearm occlusion method, as previously described [15e19, 24, 25] . The positions where the cuff is placed should contribute to different values of vasodilatory response to reactive hyperemic flow through various factors, especially difference in forces of shear stress. It is well known that NO production from endothelial cells increases in relation to the degree of shear stress. In a preliminary study, we confirmed that the value of FMD obtained by using upper arm occlusion was approximately twotimes higher than that of FMD using forearm occlusion in 50 healthy men (29.3 AE 2.3 yr, 13.9 AE 1.9% vs. 6.7 AE 1.4%, P ¼ 0.001) and in 39 patients with CVDs (29 men and 10 women, 63.1 AE 7.2 yr, 8.7 AE 1.6% vs. 4.1 AE 1.2%, P ¼ 0.002). Our results are consistent with results of previous studies showing that FMD in the brachial artery after upper arm occlusion was approximately two-times higher than FMD after forearm occlusion [19] . Since upper arm occlusion is used, the ezFMD measures will not directly be a reflection of endothelial function e rather they will be a reflection of a combination of NO and prostaglandin metabolite release. Forearm occlusion for measurement of FMD has a number of advantages. In particular, vasodilation of the brachial artery after release of the cuff placed on forearm reflects NO release more than does vasodilation induced by upper arm occlusion [19] . In the future, it is expected that a device using forearm occlusion for measurement of ezFMD will be developed. Measurement of ezFMD is based on the following two assumptions: 1) when the degree of vasodilation increases, pulsation of the brachial artery cross-sectional area increases and 2) when the brachial artery cross-sectional area increases, oscillation amplitude increases. We believe that the theoretical concept concerning measurement of ezFMD is correct since the two assumptions for measurement of ezFMD were confirmed using a simulation model in a preliminary study.
In conclusion, we demonstrated for the first time the feasibility of a new method that can automatically assess endothelial function, named ezFMD. Conventional FMD is measured by changes in brachial artery diameter, whereas ezFMD is measured by changes in vessel volume in the brachial artery. In addition, ezFMD is automatically measured using a device with an oscillometric method. Therefore, we emphasize that measurement of ezFMD is easier and less biased than conventional FMD measurement. Further studies are needed to determine whether ezFMD is a predictor of cardiovascular outcomes in a large clinical trial. In addition, we should compare the ROC curves of ezFMD and FMD for diagnosing CVD outcomes.
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